Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 214

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Molecular Classification of Breast Cancer: Limitations and Potential

Open access
Pusztai, Lajos, Mazouni, Chafika, Anderson, Keith, Wu, Yun, Symmans, W. Fraser·2006·The Oncologist

Abstract

Learning Objectives: After completing this course, the reader will be able to: Discuss the technical variables that affect accuracy of estrogen receptor immunohistochemistry.Describe emerging methods to quantify estrogen receptor expression and predict the prognosis of estrogen receptor-positive patients.Discuss limitations of current gene expression-based molecular classification of breast cancer.Explain the conceptual differences between unsupervised molecular class discovery methods and supervised clinical outcome prediction models such as multigene prognostic signatures.Interpret results of DNA microarray literature as they relate to diagnosis and prognosis of breast cancer. Access and take the CME test online and receive 1 AMA PRA Category 1 Credit™ at CME.TheOncologist.com Reverse transcription polymerase chain reaction and DNA microarrays are increasingly used in the clinic and in clinical research as prognostic or predictive tests. Results from these tests led to novel risk stratification methods and to new molecular classification of breast cancer. Some of these tools already complement existing diagnostic tests and can aid medical decision making in some situations. Better understanding of the molecular classes of breast cancer, independent of their prognostic and predictive values, may also lead to new biological insights and eventually to better therapies that are directed toward particular molecular subsets. However, there is substantially less experience with these emerging technologies than with the more established methods, the accuracy of which is often overestimated. This review discusses some of the limitations and strengths of current gene expression-based molecular classification of breast cancer. To provide context for this discussion, we also briefly examine the performance of estrogen receptor immunohistochemistry, which represents an essential part of the routine diagnostic workup for all breast cancer patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1634/theoncologist.11-8-868

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 214

Metadata

Authors
Pusztai, L., Mazouni, C., Anderson, K., Wu, Y., & Symmans, W. F.
Venue
The Oncologist
Published
2006-09-01
Volume
11
Issue
8
Pages
868-877
ISSN
  • 1083-7159 (ISSN-L)
  • 1549-490X
OpenAlex
W2164457061
Cited by
214
References
5
FWCI
3.89
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Molecular Classification of Breast Cancer: Limitations and Potential. https://app.cochat.ai/papers/10.1634/theoncologist.11-8-868
The paper
Pusztai, L., Mazouni, C., Anderson, K., Wu, Y., & Symmans, W. F. (2006). Molecular Classification of Breast Cancer: Limitations and Potential. The Oncologist. https://doi.org/10.1634/theoncologist.11-8-868

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.